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Abstract
Acetazolamide is the standard carbonic anhydrase (CA) inhibitor used for acute
mountain sickness (AMS), however some of its undesirable effects are related
to intracellular penetrance into many tissues, including across the blood–brain
barrier. Benzolamide is a much more hydrophilic inhibitor, which nonetheless
retains a strong renal action to engender a metabolic acidosis and ventilatory
stimulus that improves oxygenation at high altitude and reduces AMS. We
tested the effectiveness of benzolamide versus placebo in a first field study of
the drug as prophylaxis for AMS during an ascent to the Everest Base Camp
(5340 m). In two other studies performed at sea level to test side effect differ-
ences between acetazolamide and benzolamide, we assessed physiological actions
and psychomotor side effects of two doses of acetazolamide (250 and 1000 mg)
in one group of healthy subjects and in another group compared acetazolamide
(500 mg), benzolamide (200 mg) and lorazepam (2 mg) as an active compara-
tor for central nervous system (CNS) effects. At high altitude, benzolamide-
treated subjects maintained better arterial oxygenation at all altitudes (3–6%
higher at all altitudes above 4200 m) than placebo-treated subjects and reduced
AMS severity by roughly 50%. We found benzolamide had fewer side effects,
some of which are symptoms of AMS, than any of the acetazolamide doses in
Studies 1 and 2, but equal physiological effects on renal function. The psy-
chomotor side effects of acetazolamide were dose dependent. We conclude that
benzolamide is very effective for AMS prophylaxis. With its lesser CNS effects,
benzolamide may be superior to acetazolamide, in part, because some of the
side effects of acetazolamide may contribute to and be mistaken for AMS.
Abbreviations
AMS, acute mountain sickness; ANOVA, analysis of variance; CA, carbonic anhy-
drase; SaO2, arterial hemoglobin oxygen saturation.
Introduction
Carbonic anhydrase (CA) inhibition with acetazolamide
(DiamoxR) reduces the incidence and symptomatology of
acute mountain sickness (AMS) (Forward et al., 1987;
Wright et al., 1983; Birmingham Medical Research Expe-
ditionary Society Acute Mountain Sickness Study Group
[BMRES] 1981; Swenson, 2014a). These benefits are a
result of improved arterial oxygenation arising from the
well-known ventilatory stimulation by this drug due lar-
gely to its inhibition of renal CA and generation of a
metabolic acidosis (Kronenberg and Cain, 1968a; Larson
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et al. 1982; Swenson and Teppema 2007). Not surpris-
ingly, acetazolamide has become the drug of choice for
AMS prophylaxis (Bärtsch and Swenson, 2013; Luks et al.
2010). There is, however, an unavoidable disadvantage
with acetazolamide and other clinically approved CA inhi-
bitors, such as methazolamide, in that several of its side
effects are the same as some AMS symptoms, particularly
headache, drowsiness, and nausea or vomiting (Wang
et al. 2013). Thus, it is plausible that the efficacy of aceta-
zolamide in AMS may be underestimated (Ellsworth et al.
1987; Swenson 2014a) and that a CA inhibitor with fewer
side effects by virtue of lesser central nervous system
(CNS) penetrance would be more effective against AMS,
avoid diagnostic confusion, and afford clearer evaluation
of the benefits of targeted CA inhibition.
Benzolamide is a 10-fold more potent CA inhibitor and
is more hydrophilic and less lipophilic than acetazolamide
(Travis 1969). These attributes lead to very limited mem-
brane permeability, restricting its uptake into the central
and peripheral nervous systems and other organs besides
the kidneys. The kidneys are uniquely sensitive to any of
the sulfonamide CA inhibitors, independent of lipid and
water solubility, because organic acid transporters in the
renal tubule concentrate the drugs intracellularly and in
the tubular fluid to fully inhibit renal enzyme at low
doses (Swenson, 2014a). On this basis, benzolamide
should likely have less CNS side effects of acetazolamide,
and thus be of greater value at high altitude. These pre-
dictions and conclusions have never been adequately
tested, but in two small studies, benzolamide was shown
to be effective in reducing AMS symptomatology in a 3-
day hypoxic chamber simulation (Kronenberg et al.,
1968a) and against sleep-related periodic breathing at
high altitude (Swenson et al. 1991). Based on the work
showing beneficial effects of benzolamide on subretinal
fluid absorption in rabbits (Wolfensberger et al. 2000),
benzolamide was substituted for acetazolamide in univer-
sity age patients with macular edema. These students
found examination work easier than when taking acetazo-
lamide (A. C. Bird, Moorfields Eye Hospital, London,
unpublished observations).
Despite a considerable literature on the efficacy of aceta-
zolamide for the prophylaxis and treatment of AMS, there
has been much controversy concerning its optimal dosing
with advocacy of doses ranging from 250 to 1000 mg daily.
There has been some resolution toward lower dosing
recently with demonstration that doses as low as 125 mg
bid are as effective as higher doses, at least for typical ascent
profiles. With lower dosing there may be fewer side effects
(Basnyat et al. 2006; Van Patot et al. 2008).
The hypotheses tested herein were that benzolamide,
which remains an orphan drug since its first testing in
humans more than 50 years ago and never tested under
field conditions for AMS prevention, is effective in
increasing arterial oxygenation and preventing AMS dur-
ing a high-altitude expedition. Underlying this proposed
effectiveness and possible superiority of benzolamide over
acetazolamide is the likelihood that benzolamide has
fewer CNS side effects than acetazolamide, when tested in
a rigorous double-blinded placebo-controlled fashion with
an active comparator, lorazepam, known to alter CNS
function (Dawson et al.2008). We found that benzo-
lamide is effective in reducing AMS during a high-altitude
trek up to 5430 m and this efficacy is associated and cor-
related with improvements in arterial oxygenation. At sea
level, benzolamide has fewer CNS side effects than aceta-
zolamide at all doses studied.
Materials and Methods
Study 1: effectiveness of benzolamide
during a high-altitude trek
For the high-altitude investigation (Study 1) examining
the effectiveness of benzolamide on oxygenation and
AMS during a Himalayan trek, volunteers were recruited
from the membership of the British Mount Everest Medi-
cal Expedition. Data were collected and entered before
the randomization codes were broken. All subjects gave
written informed consent to these studies, following
approval by the Ethics Committee of the City and Hack-
ney Health Authority, London, United Kingdom. The
high-altitude study was conducted in accordance with the
CONSORT guidelines on the performance and reporting
of clinical trials (Begg et al. 1996).
During the high-altitude study 25 volunteers each
received either 100 mg benzolamide or matching placebo
capsules twice daily in a double-blind placebo-controlled
manner. Individual volunteers were assigned to benzo-
lamide or placebo prior to leaving the U.K. A third party
produced the allocation schedule, treatment was assigned
randomly (without replacement) to the list of volunteers.
Capsules of placebo were visually indistinguishable from
benzolamide and were packed and labeled by an indepen-
dent pharmacist. Tablets were begun 1 day before leaving
Kathmandu (1250 m) for an internal air flight to Lukla
(2800 m), and subjects then trekked to Everest base camp
(5340 m) following a conservative ascent profile, climbing
no more than 300 m per day above 3000 m, and taking a
rest day every 2–3 days (Ward et al. 1995). Subjects were
the members of different parties (separated in time) dur-
ing the ascent to base camp.
All subjects completed the Lake Louise consensus ques-
tionnaire, a standardized AMS questionnaire (Hackett
and Oelz, 1992), and measured and recorded their oxygen
saturation by pulse oximetry (Nellcor N20, Minneapolis,
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MN, USA) each morning and evening. On arrival at base
camp, 11 of the subjects had arterialized capillary blood
sampled from a warmed thumb and analyzed using a
Ciba-Corning 248 (Medfield, MA, USA) blood gas ana-
lyzer. Of these 11 subjects, eight were later found to have
taken placebo, and three benzolamide. This imbalance
was not planned, but was simply a random result of the
fact that blood gas analysis was not available for all sub-
jects arriving at base camp due to an avalanche blast that
temporarily halted some measurements dependent on
instrumentation in the affected research tents. Although
the study was not designed to compare side effects of
benzolamide against those of placebo, all subjects were
asked after arrival at base camp, what symptoms they had
experienced. This was before the sealed code was broken.
The code was broken at base camp (5340 m) after data
collection was complete.
Studies 2 and 3: CNS effects of
acetazolamide and benzolamide at sea level
We performed two placebo-controlled, randomized, dou-
ble-blind, cross-over studies with university-level students
(age range 18–32 years) at sea level (London, UK) to
examine the physiological and psychometric effects of
benzolamide and acetazolamide.
In the first study (Study 2), 15 fasting volunteers
attended the laboratory on the same day each week for
four consecutive weeks at 8:30 AM. They emptied their
bladders and underwent a series of psychometric and
related tests described below.
Three matching treatments were given: a single dose of
(1) placebo, (2) acetazolamide 250 mg, or (3) acetazo-
lamide 1000 mg. The different tablets were identical and
a test battery, including a urine collection, was performed
at 0, 2, 4.5, and 6.5 h postdosing. For this study, arterial-
ized capillary blood gas analysis was performed during
each test battery from a warmed ear lobe using a Ciba-
Corning 248 analyzer. End-tidal carbon dioxide tension
was also measured, after 5 min of sitting rest, using an
infra red carbon dioxide analyzer (PK Morgan Capno-
graph, Chatham, Kent, UK).
The second study (Study 3) was of similar design to
the first and was performed over a 4-week period of time.
After subjects emptied their bladders, they were each wit-
nessed taking a single dose of (1) placebo, (2) lorazepam
2 mg (a positive control for neuropsychological changes),
(3) acetazolamide 500 mg, or (4) benzolamide 200 mg
according to a Latin square design. Capsules containing
each of the four preparations were of identical appear-
ance, smell, and taste. Urine collections and the test bat-
tery were performed at 0, 2, 4.5, and 6.5 h after dosing.
In both the studies, the subjects were randomized such
that each took one of the four drugs each week so that at
the end of the 4 weeks each subject had taken all four
drugs in a randomized order.
The psychometric test battery for Studies 2 and 3 com-
prised a series of tests including critical flicker fusion
(CFF), reaction time assessment (Study 3 only), peg and
washer placement timing, postural sway assessed using a
force platform, and vertical judgment error. Intraocular
pressure (by noncontact tonometry) was also measured.
Each of these tests was performed three times at each
time interval and the arithmetic mean of the three results
was used to describe subject performance in each test at
each interval. A series of visual analog scales were also
completed which assessed subjective sleepiness, clear
headedness, and dizziness as well as control questions
about hunger and feeling hot or cold. These objective and
self-reported measures were designed to elicit symptoms
that could easily be confused with presentations of AMS
as well as the known physiological effects of these drugs.
Urinary pH and volume were determined at each time
interval. Each subject was also asked about any side
effects they had experienced while taking any of the
drugs.
For Studies 2 and 3 (at sea level), the measures for each
test were compared between the different control and
treatment groups by means of a general linear model for
analysis of variance (ANOVA). Dunnett’s test was used to
determine pairwise comparisons of data. For the high-
altitude study (Study 3), AMS scores and mean SaO2 val-
ues at various altitudes were compared using the paired t-
test and ANOVA. Arterialized capillary blood gas analysis
results between the two groups at Everest base camp were
compared using the unpaired t-test. A linear regression
model was calculated for the relationship between arterial
oxygen saturation and AMS score, with ANOVA used to
test significance; P < 0.05 was considered as significant.
Statistics were calculated using Minitab.
Results
Study 1: effectiveness of benzolamide
during a high-altitude trek
Twenty-five subjects completed the study, 13 with placebo
and 12 with benzolamide. Three subjects inadvertently vio-
lated the protocol, one subject (D. J. C.) had to descend for
a prolonged period to attend to logistical problems with
research equipment and so had a grossly atypical ascent
profile (placebo group). Another subject’s flight from
Kathmandu to Lukhla was delayed, but he had started his
tablets nonetheless, and so ran out of tablets at 4930 m
(Lobuche), and was without tablets for 2 days before arri-
val at base camp. The third subject had not declared any
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respiratory difficulties previously, but proved to have sig-
nificant chronic obstructive pulmonary disease. These sub-
jects were therefore excluded from the per-protocol
analysis, but were included in the primary intention-to-
treat analysis to avoid bias – even though the protocol vio-
lations were all decided prior to unmasking the study. Sub-
jects taking placebo reached base camp after a median of
13 days (mean = 12.6, SD = 2.1; range, 8–14 days), sub-
jects on benzolamide took a median of 12 days (mean
= 12.0, SD = 2.2; range, 9–15 days, P = 0.4, nonsignificant
difference by Mann–Whitney U test).
Subjects taking benzolamide experienced significantly
less AMS particularly during the higher elevations of the
trek. The average AMS scores on arrival at each new alti-
tude during the ascent are shown in Figure 1. Compar-
ison of average AMS scores on placebo and benzolamide
showed significantly lower values on the drug (paired
t-test; placebo average 2.18, benzolamide average 1.28,
mean difference 0.90, SEM 0.37, t = 2.46, P = 0.025, one-
sided). It can be seen that benzolamide produced a signif-
icant reduction in AMS symptomatology. The median
scores for placebo are higher than for benzolamide for
the last two stopover sites and arrival at base camp
(5340 m). This was significant at base camp (P < 0.025,
per-protocol analysis). There was also a significant differ-
ence for the worst scores (*P = 0.02, intention-to-treat
analysis; P < 0.005, per-protocol analysis). Considered
overall by ANOVA, the reductions in AMS on benzo-
lamide were significant (P = 0.02, intention-to-treat anal-
ysis) or highly significant (P = 0.003, per-protocol
analysis).
Figure 2 shows the mean values of arterial oxygen satu-
rations for placebo and benzolamide-treated subjects on
arrival at each altitude (stopover sites). At all sites from
Pheriche (4240 m) and above up to Everest Base Camp,
arterial oxygen saturation was statistically significantly
higher in the subjects taking benzolamide.
In the 11 volunteers who had arterialized capillary
blood gas analysis on arrival at 5340 m, pH, PaCO2
and bicarbonate were all lower in those treated with
benzolamide than for subjects on placebo (Table 1).
With benzolamide the average pH was 7.41 (range
7.40–7.41), whereas on placebo average pH was 7.44
(range 7.41–7.47; P = 0.003, 95% CI = 0.016, 0.053:
unpaired t-test). Arterialized capillary PCO2 was lower
on benzolamide, averaging 23.6 mmHg (range
22.8–24.3 mmHg), compared with 27.0 mmHg on pla-
cebo (range 24.3–32.0 mmHg; P < 0.01, 95% CI = 0.16,
0.77: unpaired t-test). Mean bicarbonate concentration
was lower, 17.7 mmol/L (range 17.5–17.8 mmol/L) in
the benzolamide group and 20.6 mmol/L (range 19.5–
22) in the placebo group (P < 0.0001, t = 9.0, 95%
CI = 2.14, 3.62: unpaired t-test). Although the mean
arterialized PaO2 tended to be higher in the benzo-
lamide group (45.7 mmHg) than in the placebo group
(43.6 mmHg), the increase while of similar magnitude
to the fall in PaCO2 did not reach statistical signifi-
cance (P = 0.2).
Symptoms at base camp included paresthesia (8 of 12
subjects on benzolamide and 0 of 13 on placebo) and
breathlessness (0 on benzolamide and 4 on placebo). One
subject on benzolamide reported urinary frequency and
another tinnitus (persisting for several days after stopping
the drug). No subjects found the tingling troublesome.
Two subjects on benzolamide appeared to develop
significant AMS after stopping the drug (scores >10), one
having run out of the drug and the other stopping (per-
protocol analysis) on arrival at Everest base camp.
Studies 2 and 3: CNS effects of
acetazolamide and benzolamide at sea level
In both the sea level pharmacological studies a few sub-
jects were unable to attend every weekly session. In the
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Figure 1. Median acute mountain sickness (AMS) scores on arrival at each new altitude during ascent with the median values of the worst AMS
scores for comparison. The scores are given for placebo and benzolamide-treated subjects at each altitude (placebo n = 13; benzolamide n = 12
intention-to-treat analysis).
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two sea level studies, we obtained completed data sets for
21 subjects taking placebo and acetazolamide, 20 subjects
taking benzolamide, and 18 taking lorazepam.
In Study 2, the effects of the two different doses of
acetazolamide are presented in Tables A1 and A2 in the
Appendix and may be summarized as follows. Acetazo-
lamide at a dosage of 250 mg caused an increase in uri-
nary pH (P < 0.001) and a decrease in blood pH
(P < 0.01), base excess (P < 0.05), and intraocular pres-
sure (P < 0.05, combined left and right eye results). At a
dose of 1000 mg, it caused an increase in urinary pH
(P < 0 .001) and volume (P < 0.01), and a decrease in
blood pH (P < 0.001), base excess (P < 0.001), blood
bicarbonate (P < 0.01), and intraocular pressure
(P < 0.001). Although PetCO2 appeared to fall with
increasing acetazolamide dosage from 35.2 mmHg on pla-
cebo to 34.3 mmHg on 250 mg and 33.6 mmHg on
1000 mg acetazolamide the variation in responses was so
large that the average PCO2 decrease (<2 mmHg) did not
meet statistical significance. Visual analog scores (VAS) of
sleepiness (P < 0.001) and dizziness (P < 0.01) were
increased and clear headedness declined (P < 0.001) with
1000 mg acetazolamide. There were no significant differ-
ences in any of the testing measures between placebo and
250 mg acetazolamide.
In Study 3, the head-to-head comparison of placebo,
benzolamide 200 mg, acetazolamide 500 mg, and loraze-
pam 2 mg, we obtained a complete set of data for 16 sub-
jects. Inclusion of all data collected, rather than
restriction to the 16 complete data sets does not alter the
results significantly, and so all available data are included
here. Although the capsules were identical in taste, smell,
and appearance, some subjects (about 10%) guessed their
allocation code during one of the four study days.
Side effects at any time point were reported in 2/21
(10%) taking placebo, 9/18 (50%) taking lorazepam
2 mg, 10/21 (48%) taking acetazolamide 500 mg, and 5/
20 (25%) taking benzolamide 200 mg. The specific side
effects are listed in Table 2. The physiological and psy-
chometric results for each drug, for each time point, are
given in Table A3 in Appendix. Compared to placebo,
lorazepam caused a fall in CFF and number of pegs and
washers placed correctly (both P < 0.001), an increase in
postural sway (P < 0.01) and vertical error (P < 0.05).
Subjectively, lorazepam led to an increase in self-reported
dizziness, drowsiness, and decrease in clear headedness
(all, P < 0.001). Lorazepam had no significant effect on
intraocular pressure, urinary pH, or volume.
Compared to placebo, acetazolamide 500 mg caused an
increase in urinary pH and volume (P < 0.001), fall in
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Figure 2. Mean values for arterial oxygen saturation for placebo and benzolamide-treated subjects, measured by oximetry, on arrival at each
altitude (stopover site). Values are mean  SEM, per-protocol analysis (placebo n = 12; benzolamide n = 10).
Table 1. Arterialized capillary blood gases in subjects taking benzo-
lamide or placebo on arrival at 5340 m (Everest base camp).
Subject
pHa
PaCO2 PaO2
Units mmHg mmHg
Benzolamide
42 7.404 24.3 44.8
5 7.411 22.8 44.3
28 7.409 23.5 46.1
Mean 7.4081 23.61 45.1
SD 0.004 0.8 0.9
SEM 0.002 0.5 0.5
Placebo
1 7.447 26.7 46.4
7 7.41 29.6 41.3
26 7.433 32 41.6
37 7.463 25.1 41.6
53 7.435 25.7 46.1
67 7.464 24.3 47.6
69 7.466 26 42.1
63 7.419 26.9 42.7
Mean 7.442 27 43.6
SD 0.021 2.6 2.6
SEM 0.008 0.9 0.9
1P < 0.01 compared to placebo.
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intraocular pressure (P < 0.01), increase in postural sway
and vertical error (P < 0.05), an increase in dizziness, and
a decrease in clear headedness (both P < 0.001) and
drowsiness (P < 0.05), but no significant effect on CFF or
peg and washer placement.
Compared to placebo, benzolamide 200 mg caused an
increase in urinary pH (P < 0.001) and volume
(P < 0.01), but had no significant effect on CFF, postural
sway, vertical error, peg and washer placement, intraocu-
lar pressure, drowsiness, dizziness, or clear headedness.
The time course and magnitude of the diuretic effects of
acetazolamide and benzolamide are illustrated in Figure 3.
Both drugs caused a statistically significant alkaline diuresis
of equal magnitude and onset when compared to placebo.
Discussion
Our altitude study, for subjects trekking to 5340 m
(17,520 feet), confirms the effectiveness of benzolamide
100 mg bid as prophylaxis for AMS. The present study
accords with findings of a chamber study (72 h elevation
to the equivalent of 4600 m, 14,000 feet) that benzo-
lamide has prophylactic properties in regard to AMS
symptomatology (Kronenberg and Cain 1968a). The effec-
tiveness of benzolamide on arterial blood gases appears
equal to that of acetazolamide, studied in a similar cham-
ber experiment (Kronenberg and Cain 1968b). Compar-
ison of our findings with other studies suggests that
benzolamide 100 mg bid has similar efficacy to acetazo-
lamide at both 125 mg bid and 250 mg bid dosing sched-
ules in preventing AMS symptoms under similar trekking
conditions (Basnyat et al. 2003, 2006).
The other focus of our study was to critically assess
and compare side effects and physiological effects of
benzolamide and acetazolamide in a large number of
healthy subjects at sea level so as to avoid any confound-
ing effects of hypoxia and other stresses of traveling in a
new environment, which may vary from subject to sub-
ject. Taken together the data across two groups of sub-
jects showed that benzolamide at 200 mg is equally
effective as all doses of acetazolamide (250, 500,
1000 mg) in causing an alkaline diuresis, the hallmark of
renal CA inhibition. However, only acetazolamide causes
evidence of other tissue CA inhibition, in this case easily
and relatively noninvasively assessed as a reduction in
intraocular pressure as a consequence of CA inhibition in
the ciliary apparatus of the eye. In keeping with a lack of
significant tissue penetrance, particularly into the CNS,
we show that benzolamide has far fewer side effects than
acetazolamide, even at the lowest dose of acetazolamide
shown to be effective against AMS. This is unequivocally
the case for benzolamide 200 mg versus acetazolamide
500 mg since the same subjects took both doses (Study
3). Although benzolamide was not tested in the same sub-
jects taking the 250 and 1000 mg doses of acetazolamide
(Study 2), these subjects in Study 2 were similar in age,
health, and background to those in Study 3 and all sub-
jects in both studies served as their own controls by tak-
ing placebo. When the change from placebo at 6.5 h after
drug administration for the three VAS-scored symptoms
most relevant to AMS of dizziness, sleepiness, and decline
in concentration are used (Table 3), benzolamide caused
Table 2. Number of subjects complaining of specific side effects after
administration of each drug in Study 3.
Effect
Placebo
(21)
Lorazepam
(18)
Acetazolamide
(21)
Benzolamide
(20)
Headache1 2 5 (2 severe) 4
Drowsiness 1 8 4 2
Dizziness1 9 2
Tingling of
lip or limb
4 1
Numbness
of hands
2
Earache 2
Coldness 1
Vomiting1 1
Metallic taste 1
Sore throat 1
Dry eyes 1
1Symptoms common to acute mountain sickness.
Figure 3. The time courses of urine output after dosing with either
placebo, acetazolamide 500 mg, or benzolamide 200 mg. Mean
values at each time point are shown  SEM.
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the least impact, with lorazepam roughly equivalent to
the greater side effects of acetazolamide at 250 and
500 mg. The 1000 mg dose of acetazolamide had the
greatest side effect impact. The data showed a very plausi-
ble dose–response relationship for acetazolamide across
the three doses studied.
Our findings of modest but definite CNS side effects of
acetazolamide at 250 mg accord with the recent study by
Wang et al. (2013) which suggests that the side effects of
acetazolamide at this lowest dosing are not trivial. In par-
ticular, their study found significant neuropsychological
decline in the areas of concentration, cognitive processing
speed, reaction time, and short-term memory with acetazo-
lamide after 4 days even at the low dosage of 125 mg bid.
We may indeed underestimate the benefits at high altitude
of benzolamide over acetazolamide observed in our one
time dose study. The greater lipid solubility of acetazo-
lamide is more likely to cause problems as more drug
reaches the CNS with repeated dosing over several days, as
suggested by Wang et al. (2013). Because these side effects,
which are similar to those that constitute the symptom
complex of AMS, are detectable at sea level, and thus can-
not be attributable to AMS, the full effectiveness of prophy-
laxis with CA inhibition at high altitude is not realized.
Our results with benzolamide suggest that AMS prophy-
laxis with CA inhibitors might be most effectively achieved
with less lipophilic, more hydrophilic soluble drugs that
pass the blood–brain barrier with lesser capacity (Table 4).
Unfortunately, benzolamide has no patent protection
and thus it is unlikely that any pharmaceutical company
will ever market this drug. However, with an emerging
realization that plasma membrane-associated CA iso-
zymes with extracellular orientation (IX and XII) are
richly and almost uniquely expressed in cancer cells and
critical to their growth and metastatic potential (Robert-
son et al. 2004; Swietach et al. 2010), clinical develop-
ment of other membrane impermeant CA inhibitors
which block CA IX are underway and have shown
promising features. Drugs in this class would be well
worth studying in AMS, since they too like benzolamide
would be concentrated in the kidney at low doses by the
same mechanism as for benzolamide and all sulfonamide
CA inhibitors.
The basis by which acetazolamide and other CA inhibi-
tors act to reduce AMS is overwhelmingly by improve-
ment in arterial oxygenation (Roach et al. 1998;
Kazunobu et al. 2001; Muza et al. 2004), although other
mechanisms are emerging (Swenson 2014a). The
improvement in arterial oxygenation arises from renal CA
inhibition and the subsequent alkaline diuresis to decrease
the magnitude of respiratory alkalemia and its braking
action on the fullest expression of the ventilatory response
to hypoxia (Swenson 2014a). This is shown in Tables 1–
3; the latter compared our data with selected data of
others and demonstrated that the increase in ventilation
as evidenced by lowering of PaCO2 with benzolamide is
equal to that of acetazolamide.
In support of a causal pathway between arterial oxy-
genation and AMS, we found in a recent study of two
modest ascents (each of them to around 5000 m), follow-
ing an initial 5 days acclimatization at 3324 m, a definite
negative correlation between individual mean AMS scores
and SaO2 value (Brierley et al. 2012). We therefore, addi-
tionally, have explored the relationship between AMS
scores and SaO2 in this present study of benzolamide at
altitude. When we plot mean values of the AMS scores
Table 3. Change in VAS1 score from placebo at 6.5 h after drug
ingestion.
ACTZ
250
ACTZ
500
ACTZ
1000
BENZ
200 LOR 2
Dizziness 15 18 38 5 18
Decline in concentration 21 19 42 2 9
Sleepiness 15 22 28 0 15
1Visual analog score of symptom severity: range 0–100.
Table 4. PCO2 and pH data from the present study and the three other major studies.
PAPER Present study Swenson et al. 1991 Kronenberg and Cain 1968a Swenson and Hughes 1993
Drug Benz Benz Benz Acet
Duration Days 24 h 24 h 72 h Acute i.v. 24 h
Condition Altitude Sea level Chamber Chamber Sea level Sea level
pHa
Placebo 7.442 7.44 7.493 7.501 7.43 7.44
Inhibitor 7.408 7.39 7.437 7.445 7.44 7.40
PaCO2
Placebo 27.0 39.4 28.5 27.3 41.2 39.9
Inhibitor 23.6 36.0 26.7 25.8 38.0 35.3
PaCO2 fall 3.4 3.4 1.8 1.5 3.2 4.6
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against mean SaO2 values for all subjects at each altitude,
there is a significant negative AMS–SaO2 correlation, both
for the placebo and benzolamide-treated subjects individ-
ually (Figure 4) and when combined (Figure 5). Numer-
ous other studies have found a correlation (Faulhaber
et al. 2014; Roach et al. 1998; Kazunobu et al. 2001;
Tannheimer et al. 2002; Koehle et al. 2010; Roeggla et al.
1996), but not all (Roach et al. 1995; O’Connor et al.
2004). Because correlation highly suggests but does not
prove causation, and AMS itself may alter lung function
to cause further hypoxemia (Swenson 2014a,b) better
studies with attention to what degree of hypoxemia pre-
cedes the onset of AMS along with investigations of pro-
phylactic strategies that stimulate ventilation or act by
other mechanisms, such as dexamethasone, are needed
(Luks and Swenson 2011).
Our study has several limitations requiring some
acknowledgment. We did not test benzolamide directly
against acetazolamide at high altitude because we did not
have sufficient volunteers to include another arm in Study
1. Such a trial in the future is clearly deserving of study,
but it will require a greater number of subjects to prove
either noninferiority or superiority due to the efficacy
both drugs display. A second weakness of the study is that
we did not compare benzolamide directly in the sea level
study against the 250 and 1000 mg doses of acetazo-
lamide (Study 2). However, we believe that the use of pla-
cebo groups in very similar subjects does permit us to
combine results of the two studies as we did and show in
Table 3. Future head to head studies of these doses would
be useful. Finally, we chose to study the drugs for their
side effect profile at sea level to minimize any differences
due to variable influences of high altitude, cold, change in
diet, and the stress of travel and trekking on our results.
These results provide important background reference
data for the interpretation of any future comparative
study of these drugs at high altitude.
In conclusion, our investigation confirms that the
membrane impermeant CA inhibitor, benzolamide, has
prophylactic benefit against AMS and does so under field
conditions of high-altitude trekking. It acts as a ventila-
tory stimulant by virtue of its targeted action on the kid-
ney and that the beneficial effect is due to the resultant
higher arterial oxygen saturation. Extensive and well-con-
trolled psychometric testing shows that benzolamide has a
considerably lesser side effect profile than acetazolamide
at sea level, that theoretically should make it, or a similar
membrane impermeant CA inhibitor, a better choice for
AMS prophylaxis.
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Figure 4. Average acute mountain sickness score for each altitude plotted against average SaO2 for subjects on placebo (A) and on benzolamide
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Figure 5. Average acute mountain sickness (AMS) scores at each
altitude plotted against average SaO2 for all subjects. The regression
line is AMS score = 0.161SaO2 + 15.82, r = 0.840, P < 0.02.
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Appendix 1:
Table A2. Physiological results from Study 2.
Test Drug Time 0 h Time 2 h Time 4.5 h Time 6.5 h
Intraocular pressure (mmHg) Placebo 10.1 (0.9) 9.6 (0.7) 9.5 (0.6) 9.2 (0.4)
Acetazolamide 250 mg* 10.4 (0.8) 8.6 (0.6) 8.1 (0.3) 7.8 (0.6)
Acetazolamide 1000 mg*** 10.1 (0.8) 7.7 (0.5) 8.4 (0.6) 7.2 (0.5)
End-tidal PCO2 (mmHg) Placebo 34.0 (1.3) 34.4 (1.0) 35.2 (1.1) 35.5 (1.1)
Acetazolamide 250 mg 34.3 (0.9) 34.0 (1.1) 34.7 (1.1) 32.0 (0.9)
Acetazolamide 1000 mg 36.7 (1.2) 33.5 (1.2) 33.8 (1.0) 32.1 (1.7)
Blood pH Placebo 7.44 (0.01) 7.44 (0.01) 7.45 (0.01) 7.45 (0.01)
Acetazolamide 250 mg** 7.43 (0.00) 7.40 (0.01) 7.41 (0.01) 7.39 (0.01)
Acetazolamide 1000 mg*** 7.42 (0.01) 7.38 (0.01) 7.39 (0.00) 7.40 (0.01)
Blood PCO2 Placebo 35.2 (0.8) 34.8 (0.9) 33.9 (1.0) 34.5 (1.0)
Acetazolamide 250 mg 35.2 (1.2) 35.7 (1.0) 35.7 (1.0) 33.9 (0.8)
Acetazolamide 1000 mg 35.4 (0.9) 34.3 (0.8) 35.2 (0.6) 32.8 (0.7)
Blood bicarbonate (calculated) Placebo 23.7 (0.5) 23.2 (0.4) 23.1 (0.6) 23.2 (0.5)
Acetazolamide 250 mg 23.8 (0.6) 22.4 (0.8) 22.5 (0.6) 19.8 (0.4)
Acetazolamide 1000 mg** 22.9 (0.6) 20.1 (0.5) 21.2 (0.4) 20.1 (0.6)
Simple Reaction time Placebo 233.9 (9.5) 226.8 (9.4) 221.3 (9.9) 228.2 (9.9)
Acetazolamide 250 mg 236.9 (13.7) 235.3 (11.5) 213.6 (9.2) 222.0 (6.7)
Acetazolamide 1000 mg 221.6 (10.4) 227.8 (9.8) 207.2 (9.7) 224.8 (7.7)
Base Excess (mEq/L) Placebo 0.17 (0.523) 1.120 (0.509) 1.233 (0.693) 0.907 (0.591)
Acetazolamide 250 mg* 0.930 (0.700) 3.05 (0.509) 2.163 (0.831) 5.267 (0.537)
Acetazolamide 1000 mg*** 0.446 (0.975) 4.860 (0.509) 3.715 (0.501) 4.914 (0.781)
Urine pH Placebo 6.0 (0.1) 6.6 (0.15) 6.6 (0.2) 6.8 (0.1)
Acetazolamide 250 mg*** 5.7 (0.1) 7.7 (0.06) 7. 9 (0.0) 7.7 (0.0)
Acetazolamide 1000 mg*** 6.2 (0.2) 7.7 (0.06) 7.9 (0.0) 7.7 (0.0)
Urine volume (mL) Placebo 159 (28) 238 (44) 143 (22) 147 (19)
Acetazolamide 250 mg 88 (18) 401 (45) 268 (24) 345 (24)
Acetazolamide 1000 mg** 126 (20) 527 (46) 382 (46) 364 (23)
*P < 0.05, **P < 0.01 ***P < 0.001 (relative to placebo). Values shown are mean  SEM.
Table A1. Psychometric results from Study 2 (acetazolamide dosage).
Test Drug Time 0 h Time 2 h Time 4.5 h Time 6.5 h
CFF (hz) Placebo 31.4 (0.8) 32.1 (0.7) 31.1 (0.6) 30.9 (0.6)
Acetazolamide 250 mg 31.3 (1.1) 31.5 (0.8) 30.0 (0.7) 31.7 (0.8)
Acetazolamide 1000 mg 32.2 (0.7) 31.1 (0.5) 32.5 (0.5) 32.2 (0.5)
Pegs correctly placed in 2 min Placebo 32.1 (1.5) 33.5 (1.4) 32.9 (0.9) 30.8 (1.2)
Acetazolamide 250 mg 33.1 (1.3) 33.8 (1.2) 35.1 (1.4) 36.0 (1.4)
Acetazolamide 1000 mg 33.2 (1.0) 32.9 (0.8) 31.9 (0.9) 33.8 (1.0)
VAS wide awake Placebo 74.8 (5.4) 81.1 (3.7) 75.2 (6.3) 69.0 (7.3)
Acetazolamide 250 mg 77.2 (4.4) 70.1 (4.9) 59.6 (7.0) 53.9 (8.1)
Acetazolamide 1000 mg*** 77.4 (5.2) 51.6 (6.3) 34.2 (5.3) 41.3 (5.7)
VAS decline in clear headedness Placebo 15.0 (4.3) 11.3 (3.4) 9.7 (4.1) 16.6 (5.6)
Acetazolamide 250 mg 21.5 (5.5) 22.6 (4.0) 30.5 (7.5) 37.4 (7.7)
Acetazolamide 1000 mg*** 19.3 (5.6) 45.4 (6.8) 62.4 (4.1) 58.4 (8.5)
VAS dizzy Placebo 95.5 (1.8) 95.5 (1.4) 96.5 (1.1) 85.8 (4.9)
Acetazolamide 250 mg 95.5 (1.7) 92.1 (2.3) 73.1 (7.2) 70.0 (8.0)
Acetazolamide 1000 mg** 96.4 (1.7) 67.9 (7.4) 48.6 (5.3) 47.3 (8.3)
VAS hungry Placebo 42.1 (5.1) 55.4 (6.5) 9.5 (1.7) 39.4 (2.5)
Acetazolamide 250 mg 37.8 (6.9) 52.1 (6.6) 12.1 (4.2) 23.4 (4.6)
Acetazolamide 1000 mg 45.1 (7.1) 66.9 (4.7) 26.0 (7.1) 44.7 (5.1)
*P < 0.05, **P < 0.01, ***P < 0.001 (relative to placebo at and beyond 2 h). Values are mean  SEM.
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Table A3. Physiological and psychometric results in Study 3.
Test Drug Time 0 h Time 2 h Time 4.5 h Time 6.5 h
Urine pH Placebo 5.5 (0.1) 5.9 (0.1) 5.7 (0.1) 6.1 (0.1)
Lorazepam 5.6 (0.1) 6.2 (0.1) 6.2 (0.1) 6.5 (0.2)
Acetazolamide*** 5.6 (0.2) 7.5 (0.1) 7.7 (0.1) 7.4 (0.2)
Benzolamide*** 5.7 (0.1) 7.5 (0.1) 7.7 (0.1) 7.5 (0.1)
Urine vol (mL) Placebo 92 (21) 211 (30) 142 (26) 145 (31)
Lorazepam 65 (15) 225 (38) 132 (22) 132 (20)
Acetazolamide*** 81 (16) 358 (38) 301 (36) 238 (21)
Benzolamide** 100 (21) 321 (36) 265 (37) 210 (24)
CFF (Hz) Placebo 33.9 (0.9) 33.6 (0.9) 32.8 (0.8) 32.9 (0.8)
Lorazepam*** 33.7 (0.7) 30.4 (0.9) 32.6 (0.9) 31.9 (1.0)
Acetazolamide 32.9 (1.0) 33.3 (1.0) 33.5 (0.9) 33.4 (0.9)
Benzolamide 33.6 (0.6) 33.0 (0.7) 33.1 (0.7) 32.3 (0.9)
Sway (degrees) Placebo 0.53 (0.03) 0.57 (0.04) 0.57 (0.03) 0.58 (0.04)
Lorazepam** 0.56 (0.04) 0.83 (0.05) 0.69 (0.05) 066 (0.04)
Acetazolamide* 0.53 (0.04) 0.62 (0.03) 0.62 (0.04) 0.68 (0.06)
Benzolamide 0.53 (0.03) 0.52 (0.03) 0.60 (0.05) 0.63 (0.05)
Vertical error (sum of steps) Placebo 21.0 (3.1) 23.7 (3.0) 36.5 (5.6) 27.1 (5.5)
Lorazepam* 29.7 (5.7) 32.8 (7.2) 32.1 (6.9) 41.9 (8.4)
Acetazolamide* 30.2 (3.9) 44.3 (5.6) 31.1 (2.9) 30.3 (5.5)
Benzolamide 29.6 (3.9) 27.1 (3.0) 26.9 (3.3) 30.4 (3.6)
Pegs correctly placed in 2 min Placebo 34.5 (1.1) 36.1 (1.3) 34.7 (1.1) 36.6 (1.2)
Lorazepam*** 36.3 (1.0) 28.9 (1.4) 35.7 (1.9) 33.9 (1.2)
Acetazolamide 34.1 (1.1) 34.8 (1.3) 35.0 (1.2) 34.5 (1.5)
Benzolamide 33.7 (1.0) 34.0 (1.0) 34.0 (1.0) 34.8 (1.2)
VAS sleepy Placebo 66.8 (6.5) 60.5 (6.2) 65.1 (5.4) 64.2 (6.1)
Lorazepam*** 72.1 (6.4) 40.8 (7.5) 43.6 (7.7) 47.8 (6.6)
Acetazolamide* 64.8 (6.6) 51.7 (6.0) 47.3 (6.1) 42.8 (8.3)
Benzolamide 75.8 (5.5) 68.3 (6.0) 58.3 (7.4) 64.8 (6.5)
VAS clear headedness Placebo 23.3 (5.0) 25.9 (3.9) 28.6 (5.4) 28.4 (5.3)
Lorazepam*** 28.8 (6.8) 53.1 (6.7) 45.6 (6.6) 38.4 (7.2)
Acetazolamide*** 30.6 (5.9) 58.4 (5.2) 54.3 (6.0) 46.9 (7.1)
Benzolamide 17.3 (4.7) 28.8 (6.5) 35.2 (7.0) 30.6 (6.7)
VAS dizzy Placebo 80.9 (6.3) 80.9 (4.6) 73.3 (6.4) 73.9 (6.2)
Lorazepam*** 79.9 (5.8) 31.8 (6.3) 33.9 (6.1) 56.1 (8.4)
Acetazolamide*** 72.5 (7.2) 58.8 (8.2) 53.8 (8.4) 55.8 (7.8)
Benzolamide 87.5 (4.5) 82.5 (5.0) 74.7 (6.6) 79.0 (6.1)
VAS hungry Placebo 25.8 (5.7) 51.8 (6.9) 25.1 (5.3) 36.1 (6.0)
Lorazepam 28.8 (6.5) 54.0 (7.1) 25.4 (5.5) 36.1 (5.9)
Acetazolamide 33.7 (6.7) 49.9 (7.5) 20.4 (4.4) 35.3 (7.1)
Benzolamide 26.5 (5.3) 51.6 (5.3) 24.4 (5.2) 35.5 (5.5)
Intraocular pressure (mmHg) Placebo 9.8 (0.7) 10.4 (0.6) 9.0 (0.4) 9.1 (0.4)
Lorazepam 9.9 (0.6) 9.3 (0.5) 9.0 (0.5) 8.9 (0.5)
Acetazolamide** 9.0 (0.6) 7.7 (0.7) 7.7 (0.5) 8.3 (0.5)
Benzolamide 9.4 (0.6) 8.5 (0.4) 8.6 (0.5) 8.7 (0.5)
*P < 0.05, **P < 0.01, ***P < 0.001 (relative to placebo). Values are mean  SEM.
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